The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer.-MedSci.cn

The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer.

Hoang, T; Sutera, P; Nguyen, T; Chang, JH; Jagtap, S; Song, Y; Shetty, A; Chowdhury, D; Chan, A; Carrieri, FA; Song, DY; DeWeese, TL; Lafargue, A; Van der Eecken, K; Ost, FBP; Tran, PT; Deek, M

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务